natgillin/translations-raw huggingface dataset:
A compound according to claim 10 wherein R1 represents C1-6alkyl. 
Spoj sukladno patentnom zahtjevu 10 naznačeno time, da R1 predstavlja C1-6alkil.
A compound according to claim 11 wherein R1 represents methyl. 
Spoj sukladno patentnom zahtjevu 11 naznačeno time, da R1 predstavlja metil.
A compound according to claim 1, wherein the compound is or a pharmaceutically acceptable salt or solvate thereof. 
Spoj sukladno patentnom zahtjevu 1, naznačeno time, da je spoj ili njegova farmaceutski prihvatljiva sol ili solvat.
A compound according to claim 17 wherein the compound is 
Spoj sukladno patentnom zahtjevu 17 naznačeno time, da je spoj
A compound according to claim 1 wherein the compound is selected from and 
Spoj sukladno patentnom zahtjevu 1 naznačeno time, da je spoj odabran iz i
A process for the preparation of a compound of formula (I) as claimed in claim 1, which process comprises: 
Postupak za pripremu spoja formule (I) sukladno patentnom zahtjevu 1, pri čemu postupak sadrži:
reacting a compound of formula (II) with formaldehyde in the presence of a suitable solvent, at a suitable temperature, wherein R1, R2a, R2b, R2c, R3, R4 and n are as defined in claim 1; and optionally thereafter converting one compound of the formula (I) into another compound of the formula (I). 
reakciju spoja formule (II) s formaldehidom u prisutnosti pogodnog otapala, na pogodnoj temperaturi, naznačeno time, da R1, R2a, R2b, R2c, R3, R4 i n su kao što su definirani u patentnom zahtjevu 1; i izborno nakon toga pretvaranje spoja formule (I) u drugi spoj formule (I).
A compound as defined in any one of claims 1 to 19 for use in the prophylaxis or treatment of a disease state or condition mediated by a FGFR kinase. 
Spoj sukladno bilo kojem od patentnih zahtjeva 1 do 19 za uporabu u profilaksi ili tretmanu oboljenja uzrokovane FGFR kinazom.
A compound for use in the treatment of cancer according to claim 24 wherein the cancer is bladder cancer, urothelial cancer, metastatic urothelial cancer, surgically unresectable urothelial cancer, breast cancer, glioblastoma, lung cancer, non small cell lung cancer, squamous cell lung cancer, adenocarcinoma of the lung, pulmonary adenocarcinoma, small cell lung cancer, ovarian cancer, endometrial cancer, cervical cancer, soft tissue sarcoma, head and neck squamous cell carcinoma, gastric cancer, oesophageal cancer, squamous cell carcinoma of the oesophagus, adenocarcinoma of the oesophagus, cholangiocarcinoma, hepatocellular carcinoma. 
Spoj za uporabu u tretmanu karcinoma sukladno patentnom zahtjevu 24 naznačeno time da karcinom je karcinom mjehura, urotelijalni karcinom, metastatski urotelijalni karcinom, inoperabilni urotelijalni karcinom, karcinom dojke, glioblastom, karcinom pluća, nesitnostanični karcinom pluća, karcinom pluća skvamoznih stanica, adenokarcinom pluća, plućni adenokarcinom, sitnostanični karcinom pluća, karcinom jajnika, karcinom endometrija, cervikalni karcinom, sarkom mekog tkiva, karcinom glave i vrata skvamoznih stanica, karcinom želuca, karcinom jednjaka, karcinom skvamoznih stanica, karcinom jednjaka, adenokarcinom jednjaka, kolangiokarcinom, hepatocelularni karcinom.
A compound for use according to claim 25 wherein the cancer is urothelial cancer, metastatic urothelial cancer, or surgically unresectable urothelial cancer. 
Spoj za uporabu sukladno patentnom zahtjevu 25 naznačeno time da je karcinom urotelijalni karcinom, metastazirajući urotelijalni karcionom, ili inoperabilni urotelijalni karcinom.
A compound for use according to claim 25 wherein the cancer is bladder cancer. 
Spoj za uporabu sukladno patentnom zahtjevu 25 naznačeno time da karcinom je karcinom mjehura.
A compound for use according to claim 27 wherein the cancer is bladder cancer with a FGFR3 chromosomal translocation. 
Spoj za uporabu sukladno patentnom zahtjevu 27 naznačeno time da karcinom je karcinom mjehura s FGFR3 kromosomskom translokacijom.
A compound for use according to claim 27 wherein the cancer is bladder cancer with a FGFR3 point mutation. 
Spoj za uporabu sukladno patentnom zahtjevu 27 naznačeno time da karcinom je karcinom mjehura s FGFR3 točkastom mutacijom.
A compound for use in the treatment of cancer according to claim 24 wherein 
Spoj za uporabu u tretmanu karcinoma sukladno patentnom zahtjevu 24 naznačeno time da
A compound for use according to claim 25 wherein the cancer is cholangiocarcinoma. 
Spoj za uporabu sukladno patentnom zahtjevu 25 naznačeno time da karcinom je kolangiokarcinom.
A compound for use in the treatment of cancer according to claim 24 wherein the compound is 
Spoj za uporabu u tretmanu karcinoma sukladno patentnom zahtjevu 24 naznačeno time da je spoj
A compound for use according to claim 31 wherein the compound is 
Spoj za uporabu sukladno patentnom zahtjevu 31 naznačeno time da je spoj
A method of forming a compound of formula (IIIa): wherein: 
Postupak za pripremu spoja formule (IIIa):
is a C1-5 fluoroalkyl; and PG is a protecting group, the method comprising the step of reacting a compound of formula (IIa) with a compound of formula (VIII): 
je C1-5 fluoroalkil; i PG je zaštitna skupina, postupak sadrži korak reakcije spoja formule (IIa) sa spojem formule (VIII):
wherein the compound of formula (III) is formed by the method of any preceding claim and wherein PG of formula (IIIa) is a group of formula SiR33. 
pri čemu se spoj formule (III) dobiva postupkom sukladno bilo kojem prethodnom zahtjevu i pri čemu je PG iz formule (IIIa) skupina formule SiR33.
A method according to claim 9 wherein the 2-ethylhexanoate salt is a metal 2-ethylhexanoate. 
Postupak sukladno zahtjevu 9, naznačeno time, da je 2-etilheksanoatna sol metal 2-etilheksanoat.
A method according to claim 10 wherein the metal is an alkali. 
Postupak sukladno zahtjevu 10, naznačeno time, da je metal alkalni metal.
wherein the compound of formula (II) formed is used in the method of any preceding claim and wherein PG of formula (IIa) is a group of formula SiR33. 
pri čemu se dobiveni spoj formule (II) koristi u postupku sukladno bilo kojem od prethodnih zahtjeva i pri čemu je PG iz formule (IIa) skupina formule SiR33.
A polymorph according to claim 2 characterised in that it provides an XRPD pattern comprising peaks as set out in Table 4: 
Polimorf u skladu s patentnim zahtjevom 2, naznačen time što osigurava uzorak XRPD koji sadrži maksimume kao što su iznijeti u Tablici 4:
A polymorph or salt as defined in any one of claims 1 to 3 for use in the treatment of a disorder mediated by inappropriate PI3-kinase activity wherein the disorder is selected from the group consisting of respiratory diseases; viral infections; non-viral respiratory infections; allergic diseases; autoimmune diseases; inflammatory disorders; cardiovascular diseases; hematologic malignancies; neurodegenerative diseases; pancreatitis; multiorgan failure; kidney diseases; platelet aggregation; cancer; sperm motility; transplantation rejection; graft rejection; lung injuries; and pain. 
Polimorf, ili sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je namijenjen upotrebi u liječenju poremećaja uzrokovanog neodgovarajućom aktivnošću PI3-kinaze, gdje se poremećaj bira iz skupine koju čine bolesti dišnih puteva; virusne infekcije; nevirusne infekcije dišnih puteva; alergijske bolesti; autoimune bolesti; upalni poremećaji; kardiovaskularne bolesti; hematološki malignomi; neurodegenerativne bolesti; pankreatitis; višeorganska insuficijencija; bubrežne bolesti; agregacija trombocita; rak; pokretljivost sjemena; odbacivanje transplantata; odbacivanje presadaka; ozljede pluća; i bol.
Use of a polymorph or salt as defined in any one of claims 1 to 3 in the manufacture of a medicament for use in the treatment of a disorder mediated by inappropriate PI3-kinase activity wherein the disorder is selected from the group consisting of respiratory diseases; viral infections; non-viral respiratory infections; allergic diseases; autoimmune diseases; inflammatory disorders; cardiovascular diseases; hematologic malignancies; neurodegenerative diseases; pancreatitis; multiorgan failure; kidney diseases; platelet aggregation; cancer; sperm motility; transplantation rejection; graft rejection; lung injuries; and pain. 
Upotreba polimorfa, ili soli, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je polimorf namijenjen proizvodnji medikamenta namijenjenog upotrebi u liječenju poremećaja uzrokovanog neodgovarajućom aktivnošću PI3-kinaze, gdje se poremećaj bira iz skupine koju čine bolesti dišnih puteva; virusne infekcije; nevirusne infekcije dišnih puteva; alergijske bolesti; autoimune bolesti; upalni poremećaji; kardiovaskularne bolesti; hematološki malignomi; neurodegenerativne bolesti; pankreatitis; višeorganska insuficijencija; bubrežne bolesti; agregacija trombocita; rak; pokretljivost sjemena; odbacivanje transplantata; odbacivanje presadaka; ozljede pluća; i bol.
Process according to claim 1 or 2, wherein the surplus mass is collected in a collector placed in at least one of the longitudinal ends of the mould and is transferred to a container wherein said liquid resin mixture is formed, and wherein the new liquid resin mass added to the surplus mass collected outside the mould for forming the liquid resin mixture in said container, is at least equal to, preferably greater than, still more preferably at least twice, the surplus mass, so that the concentration of said active agent in the liquid mixture in said container is 50% or less than the first concentration. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se suvišnu masu prikuplja u kolektoru koji se nalazi u najmanje jednom od uzdužnih krajeva kalupa, te prebacuje u spremnik u kojem se dobiva navedenu tekuću smolnu smjesu, te što je nova masa tekuće smole dodana suvišnoj masi prikupljenoj izvan kalupa za dobivanje tekuće smolne smjese u navedenom spremniku, je u najmanju ruku jednaka, po mogućnosti veća od, još poželjnije najmanje dvostruka, u odnosu na suvišnu masu, tako da je koncentracija navedenog aktivnog sredstva u tekućoj smjesi u navedenom spremniku 50 % ili manja od prve koncentracije.
Process according to anyone of the preceding claims, comprising the step of controlling the temperature of the mould by directing a thermoregulation fluid at least towards predetermined portions of an external lateral surface of the mould itself, collecting the thermoregulation fluid falling from the mould, conveying the collected thermoregulation fluid again towards said portions of the external lateral surface of the mould; and wherein the collected thermoregulation fluid is initially supplied to a heat exchange unit in order to enable to thermally regulate the thermoregulation fluid and therefore again towards said portions of the external lateral surface of the mould. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što uključuje korak kontroliranja temperature kalupa usmjeravanjem termoregulacijskog fluida u najmanju ruku prema zadanim dijelovima vanjske bočne površine samog kalupa, prikupljanja termoregulacijskog fluida koji pada iz kalupa, transporta prikupljenog termoregulacijskog fluida ponovno prema navedenim dijelovima vanjske bočne površine kalupa; i gdje se prikupljeni termoregulacijski fluid najprije dovodi u jedinicu za izmjenu topline kako bi se omogućilo toplinsko reguliranje termoregulacijskog fluida, zatim ponovno prema navedenim dijelovima vanjske bočne površine kalupa.
Process according to claim 8, wherein the thermoregulation fluid supplied to the mould is maintained at a temperature inside a predetermined thermal range, for example at a temperature smaller than 100°C, preferably comprised between 80°C and 90°C, and the thermoregulation fluid is directed at least towards a plurality of portions of an external lateral surface of the mould itself. 
Postupak u skladu s patentnim zahtjevom 8, naznačen time što se termoregulacijski fluid kojeg se dovodi do kalupa održava na temperaturi unutar zadanog temperaturnog raspona, primjerice na temperaturi nižoj od 100 °C, po mogućnosti se kreće između 80 °C i 90 °C, gdje se termoregulacijski fluid usmjeri u najmanju ruku prema više dijelova vanjske bočne površine samog kalupa.
Process according to anyone of the preceding claims, wherein the step of inserting the liquid resin in the mould is performed by maintaining the injection nozzle in a fixed position at a terminal area of the mould, the dispensing opening being arranged inside the mould and at a predetermined distance - not greater than 1/3 of the mould axial extension - from a minimum area opening of the mould itself. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se korak unosa tekuće smole u kalup provodi držanjem injekcijske mlaznice u fiksnom položaju u krajnjem području kalupa, gdje se otvor za unos nalazi u kalupu na zadanoj udaljenosti, ne većoj od aksijalnog pružanja 1/3 kalupa, od minimalnog otvora samog kalupa.
Process according to anyone of the preceding claims, wherein the thermoregulation fluid comprises water or, preferably, oil, particularly diathermic oil, and wherein the reinforcing material comprises synthetic reinforcing fibers, such as carbon fibers, glass fibers, aramid fibre, Kevlar, boron fibre or natural reinforcing fibres such as natural fibres of animal origin or natural fibres of vegetal origin. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što termoregulacijski fluid sadrži vodu ili, po mogućnosti, ulje, osobito dijatermično ulje, te što ojačavajući materijal sadrži sintetska ojačavajuća vlakna, poput ugljičnih vlakana, staklenih vlakana, aramidnog vlakna, kevlara, bornog vlakna ili prirodnih ojačavajućih vlakana, poput prirodnih vlakana životinjskog podrijetla ili prirodnih vlakana biljnog podrijetla.
is a divalent arylene, heteroarylene, or saturated monocyclic heterocycloalkylene group; 
je odabran od dvovalentnog arilena, heteroarilena i zasićene monocikličke heterocikloalkilenske skupine;
is hydrogen or (C1-C4) alkyl optionally substituted by hydroxy or —NR11R12, wherein R11 and R12 are independently hydrogen or (C1-C4) alkyl, or, together with the nitrogen atom to which they are linked, R11 and R12 form a saturated heterocycloalkyl group having an additional heteroatom selected from the group consisting of O, S, and NH; and A is a nitrogen containing group which is: 
je odabran od vodika i (C1-C4) alkila koji može biti supstituiran s hidroksi ili -NR11R12 te gdje R11 i R12 jesu neovisno odabrani od vodika, (C1-C4) alkila, ili, zajedno s dušikovim atomom za koji su vezani mogu tvoriti zasićenu heterocikloalkilnu skupinu koja ima dodatni heteroatom odabran od O, S i NH; A je skupina koja sadrži dušik koja je odabrana od:
a group (a) which is —(CH2)s—NR8R9 wherein s is an integer ranging from 1 to 4 and R8 and R9 are independently hydrogen or (C1-C4) alkyl; or 
skupina (a) koja je -(CH2)s-NR8R9 gdje je s cijeli broj u rasponu od 1 do 4 te R8 i R9 neovisno jesu vodik ili (C1-C4) alkil; te
The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is selected from the group represented by the following Chemical Formulae 1-2 to 1-4: in Chemical Formulae 1-2 to 1-4, R1 to R5 are as defined in claim 1. 
Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen time što je spoj odabran iz skupine koja se sastoji od slijedećih kemijskih formula 1-2 do 1-4: u kemijskim formulama 1-2 do 1-4, do R5 su kao što je definirano u zahtjevu 1.
The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is selected from the group consisting of the following compounds: 
Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen time što je spoj odabran iz skupine koja se sastoji od slijedećih spojeva:
A pharmaceutical composition for use in the prevention and treatment of 5-HT receptor-mediated or muscarinic acetylcholine receptor-mediated diseases selected from depression, manic depression, schizophrenia, autism, obsessive-compulsive neurosis, anxiety disorder, migraine, hypertension, eating disorder, irritable bowel syndrome (IBS), peptic ulcer, diabetic neuropathy, asthma, and overactive bladder, comprising the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 10. 
Farmaceutski pripravak naznačen time što je za uporabu za prevenciju i liječenje bolesti posredovanih receptorom 5-HT ili bolesti posredovanih muskarinskim acetilkolinskim receptorima odabranih od depresije, manične depresije, shizofrenije, autizma, opsesivno-kompulzivne neuroze, poremećaja anksioznosti, migrene, hipertenzije, poremećaja prehrane, sindroma iritabilnog crijeva (IBS), peptičkog ulkusa, dijabetičke neuropatije, astme, i preaktivnog mokraćnog mjehura, koji sadrži spoj ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od zahtjeva 1 do 10.
The crystal according to claim 1, wherein the crystal has characteristic peaks at diffraction angles of 2θ (± 0.5°) = 8.6°, 10.2°, 13.3°, 14.4°, 18.5°, 19.9°, 21.8°, 25.1°, 25.6°, 26.6°, 27.1° and 29.5° in its powder X-ray diffraction spectrum. 
Kristal prema zahtjevu 1, naznačen time što kristal ima karakteristične vrhove kod kutova difrakcije od 2θ (± 0.5°) = 8.6°, 10.2°, 13.3°, 14.4°, 18.5°, 19.9°, 21.8°, 25.1°, 25.6°, 26.6°, 27.1° i 29.5° u njegovom spektru rendgenske difrakcije praha.
The crystal according to claim 15, wherein the crystal has characteristic peaks at diffraction angles of 2θ (± 0.5°) = 7.2°, 10.9°, 13.3°, 15.9°, 18.2°, 20.8°, 22.1°, 25.2°, 26.1° and 29.1° in its powder X-ray diffraction spectrum. 
Kristal prema zahtjevu 15, naznačen time što kristal ima karakteristične vrhove kod kutova difrakcije od 2θ (± 0.5°) = 7.2°, 10.9°, 13.3°, 15.9°, 18.2°, 20.8°, 22.1°, 25.2°, 26.1° i 29.1° u njegovom spektru rendgenske difrakcije praha.
The crystal according to claim 1, wherein the crystal has characteristic peaks at diffraction angles of 2θ (± 0.5°) = 7.2°, 12.5°, 13.0°, 14.7°, 19.2°, 20.0°, 21.4°, 21.7°, 24.7° and 26.0 in its powder X-ray diffraction spectrum. 
Kristal prema zahtjevu 1, naznačen time što kristal ima karakteristične vrhove kod kutova difrakcije od 2θ (± 0.5°) = 7.2°, 12.5°, 13.0°, 14.7°, 19.2°, 20.0°, 21.4°, 21.7°, 24.7° i 26.0 u njegovom spektru rendgenske difrakcije praha.
A crystal of the compound according to claim 14. 
Kristal spoja prema zahtjevu 14.
The compound or the crystal according to any one of claims 1 to 17 for use in treating or preventing a disease associated with xanthine oxidase, wherein the disease is selected from the group consisting of gout, hyperuricemia, tumor lysis syndrome, urinary calculi, hypertension, dyslipidemia, diabetes, cardiovascular diseases, kidney diseases, respiratory diseases, inflammatory bowel diseases and autoimmune diseases. 
Spoj ili kristal prema bilo kojem od zahtjeva 1 do 17 naznačen time što je za uporabu za liječenje ili prevenciju bolesti povezane s ksantin oksidazom, pri čemu je bolest odabrana iz skupine koju čine giht, hiperuricemija, sindrom lize tumora, bubrežni kamenci, hipertenzija, dislipidemija, dijabetes, kardiovaskularne bolesti, bolesti bubrega, respiratorne bolesti, upalne bolesti crijeva i autoimune bolesti.
A method for producing the crystal according to any one of claims 2 to 5, comprising the steps of: suspending an alkyl ester of 4-methyl-2-[4-(2-methylpropoxy)-3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]-1,3-thiazole-5-carboxylic acid in a solvent and performing hydrolysis by adding an aqueous solution of a base thereto; and 
Postupak za proizvodnju kristala u skladu s bilo kojim od zahtjeva 2 do 5, naznačen time što sadrži korake: suspendiranje alkil estera 4-metil-2-[4-(2-metilpropoksi)-3-(1H-1,2,3,4-tetrazol-1-il)fenil]-1,3-tiazol-5-karboksilne kiseline u otapalu i provođenje hidrolize dodavanjem vodene otopine baze; i neutraliziranje reakcijskog produkta.
neutralizing the reaction product. The method according to claim 20, further comprising the step of adding water to the neutralized product and stirring it. 
Postupak prema zahtjevu 20, naznačen time što nadalje sadrži korak dodavanja vode u neutralizirani proizvod i njegovo miješanje.
The method according to claim 22 or 23, wherein the solvent is selected from the group consisting of ethers, ketones, esters, alcohols, water, and a mixture solvent thereof. 
Postupak prema zahtjevu 22 ili 23, naznačen time što je otapalo je odabrano iz skupine koja se sastoji od etera, ketona, estera, alkohola, vode i njihove smjese otapala.
is selected from the group consisting of CH and CR4, and X6 is selected from the group consisting of NH and N-CH2-(phenyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, C1-9 amino, C1-8 alkylamino, C1-5 oxycarbonyl, cyano, halo, hydroxy, nitro, and trifluoromethyl); or 
je odabran iz skupine koju čine C1-6 alkil, C3-8cikloalkil, i fenil po izboru supstituiran s 1 do 5 supstituenata koji su neovisno odabrani iz skupine koju čine C1-4 alkil, C1-4 alkoksi, C1-9 amid, amino, C1-8 alkilamino, C1-5oksikarbonil, cijano, halo, hidroksil, nitro, C1-8 sulfonil, i trifluorometil; je odabran iz skupine koju čine:
to Y20 are nucleotides complementary to X2 to X18; and 
doY20su nukleotidi komplementarni nukleotidima X2 doX18; i
The process according to claim 1 wherein the antisolvent B is maintained under stirring and at a temperature below 50°C. 
Postupak prema zahtjevu 1 naznačen time što se protuotapalo B održava uz miješanje i pri temperaturi ispod 50°C.
The process according to claim 3, wherein the step a) comprises obtaining a solution of the gadobenate dimeglumine in water or an aqueous solvent A with a concentration of the gadobenate dimeglumine at least 50% w/w. 
Postupak prema zahtjevu 3 naznačen time što korak a) obuhvaća dobivanje otopine gadobenat dimeglumina u vodi ili vodenom otapalu A s koncentracijom od najmanje 50% m/m.
The process according to claim 7, wherein the solution of the gadobenate dimeglumine comprises an amount of water or a residual aqueous solvent which, by weight, is less than 35% of the amount by weight of the gadobenate dimeglumine in solution. 
Postupak prema zahtjevu 7 naznačen time što organska otopina sadrži količinu vode ili preostalog vodenog otapala koja je, po masi, manja od 35% masenog udjela gadobenat dimeglumina u otopini.
The process according to claim 10 wherein the antisolvent B is maintained under stirring at a temperature of from 0 to 10 °C. 
Postupak prema zahtjevu 10 naznačen time što se protuotapalo B održava uz miješanje pri temperaturi od 0 do 10 °C.
The process according to claim 11, wherein the addition of the solution of the gadobenate dimeglumine to the antisolvent B is performed in a time ranging from 1 to 8 hours. 
Postupak prema zahtjevu 11 naznačen time što se dodavanje otopine gadobenat dimeglumina u protuotapalo B provodi u vremenu u rasponu od 1 do 8 sati.
The process according to claim 7, wherein the step b) comprises adding the obtained solution of the gadobenate dimeglumine to an antisolvent B having a log P value ranging from −0.5 to about 2.0, wherein the log P value of the antisolvent B exceeds the log P value of the solvent A by a value ranging from 0.25 to about 3.5. 
Postupak prema bilo kojem od zahtjeva 7 - 9 naznačen time što korak b) obuhvaća dodavanje dobivene organske otopine gadobenat dimeglumina u protuotapalo B koje ima vrijednost log P u rasponu od -0.5 do oko 2.0, te prekoračuje vrijednost za organsko otapalo A za vrijednost u rasponu od 0.25 do oko 3.5.
The process according to claim 14 wherein the antisolvent B is maintained under stirring and at a temperature from 10 to 25 °C. 
Postupak prema zahtjevu 14 naznačen time što se protuotapalo B održava uz miješanje i pri temperaturi od 10 do 25 °C.
The process according to claim 1, wherein the step a) of the process comprises obtaining a solution of the gadobenate dimeglumine by solubilizing a water insoluble or hardly workable gummy or glassy solid form of the gadobenate dimeglumine in a solvent A. 
Postupak prema zahtjevu 1 naznačen time što korak a) postupka obuhvaća dobivanje otopine gadobenat dimeglumina solubilizacijom u vodi netopivog ili teško obradivog gumastog ili staklastog krutog oblika navedenog kompleksa spoja u otapalu A.